¶ long-chain acyl-CoA dehydrogenase
¶ Definition
Mitochondrial matrix enzyme that catalyzes the first dehydrogenation step of Beta-oxidation for long-chain fatty acid (C12-C18). LCAD is part of a family of acyl-CoA dehydrogenases with chain-length specificity, essential for converting stored fat into energy during Intermittent fasting, physical activity, and overnight sleep. Deficiency causes profound metabolic inflexibility and energy crisis during fasting states.
¶ Picture It
Think of LCAD as the first checkpoint in a disassembly factory for long fat molecules. Imagine a conveyor belt carrying 18-link chains (fatty acids) into the mitochondrial factory floor. LCAD is the first worker who grabs each chain, removes two hydrogen atoms (like unclipping two safety pins), and creates a kink (double bond) between links 2 and 3. This kink weakens the chain so the next worker can snap off a 2-link segment. LCAD hands the hydrogen atoms to a courier (electron-transferring flavoprotein) who rushes them to the power plant (respiratory chain) to make ATP. The kinked chain moves down the conveyor belt to the next enzyme. Without LCAD, the factory can't process long chains—imagine trying to burn tree trunks in a fireplace designed for kindling. The trunks just pile up (fat accumulates), and the house goes cold (hypoglycemia, no ketones) because there's no fuel being processed.
¶ Mechanism
LCAD operates via FAD-dependent dehydrogenation at the mitochondrial matrix:
- Substrate binding: Long-chain acyl-CoA (C12-C18) binds to LCAD active site containing FAD cofactor
- Dehydrogenation: LCAD removes two hydrogen atoms from α-carbon (C-2) and β-carbon (C-3) positions → creates trans-Δ²-enoyl-CoA (double bond between C-2 and C-3)
- Electron transfer: FAD reduced to FADH₂ → transfers electrons to electron-transferring flavoprotein (ETF) → ETF transfers to ETF-ubiquinone oxidoreductase → feeds electrons into Complex III of respiratory chain
- Product release: Trans-enoyl-CoA released → proceeds to enoyl-CoA hydratase (second enzyme in β-oxidation spiral)
- Enzyme family coordination:
- LCAD handles C12-C18
- MCAD (medium-chain) handles C6-C10
- SCAD (short-chain) handles C4-C6
- Each enzyme hands off progressively shorter chains until complete oxidation to acetyl-CoA
Regulatory factors:
- PPAR-α upregulates LCAD expression during Intermittent fasting
- PGC-1α enhances transcription during physical activity
- Insulin suppresses LCAD activity (fed state prioritizes glucose)
- Glucagon and Adrenaline enhance LCAD expression via PKA signaling
¶ Clinical Significance
LCAD deficiency reveals the critical bottleneck in metabolic flexibility—the ability to switch from glucose to fat oxidation. This is central to Metamodel 3 (metabolic system) and the concept of the Selfish Brain prioritizing glucose when fat oxidation fails.
Clinical presentations of LCAD deficiency:
- Hypoketotic hypoglycemia: Blood glucose
.0 mmol/L without compensatory ketone production during fasting >12 hours - Exercise intolerance: Inability to sustain physical activity beyond glycogen stores (90-120 minutes)
- Cardiomyopathy: Heart muscle cannot oxidize long-chain fats → accumulation of toxic acyl-CoA intermediates → dilated cardiomyopathy
- Rhabdomyolysis: Muscle breakdown during prolonged exercise when fat oxidation fails
- Hepatomegaly: Fatty liver from accumulated long-chain fatty acids
Evolutionary mismatch implications:
Our Hunter-Gatherer Phenotype ancestors relied on LCAD during extended periods between successful hunts (24-72 hour fasts). Modern feeding patterns (every 3-4 hours) never challenge LCAD capacity, leading to:
- Undiagnosed partial LCAD deficiency manifesting only during Intermittent fasting protocols
- "Keto flu" in some individuals may reflect subclinical fatty acid oxidation enzyme insufficiency
- Explains why some patients cannot tolerate low-carbohydrate diets despite theoretical benefits
Intervention framework:
- Assess fat oxidation capacity: Respiratory quotient (RQ) >0.90 during fasting suggests poor fat oxidation
- MCT oil supplementation: Medium-chain triglycerides bypass LCAD (go directly to MCAD) → provides ketogenic substrate
- Gradual fasting protocols: Build fat oxidation enzyme capacity over 4-8 weeks (incrementally extend fasting windows)
- Carnitine supplementation: Required cofactor for acyl-CoA transport into mitochondria (rate-limiting in some cases)
- Avoid sudden low-carb transitions: Risk precipitating metabolic crisis if LCAD capacity insufficient
Connection to chronic inflammation:
Failed fat oxidation → accumulation of long-chain acyl-CoA → activates NLRP3 inflammasome → IL-1β and IL-6 release → insulin resistance → further impairs metabolic flexibility (vicious cycle)
¶ Key Facts
- First and rate-limiting enzyme for long-chain fatty acid oxidation (C12-C18)
- Located exclusively in mitochondrial matrix (requires fatty acid entry via CPT1A)
- FAD-dependent enzyme (riboflavin/vitamin B2 deficiency impairs function)
- Transfers electrons to ETF → respiratory chain → generates ~1.5 ATP per dehydrogenation
- Activity peaks during overnight fasting (12-16 hours) and sustained exercise (>90 minutes)
- LCAD deficiency: autosomal recessive, prevalence ~1:40,000-100,000 births
- Diagnosis: elevated C12-C18 acylcarnitines on newborn screening or during metabolic stress
- Part of acyl-CoA dehydrogenase superfamily (ACAD gene family)
- Upregulated 3-5 fold by PPAR-α agonists (e.g., Intermittent fasting, physical activity)
- Inhibited by high insulin states and continuous feeding patterns
- Cannot oxidize short- or medium-chain fatty acids (requires MCAD/SCAD handoff)
- Genetic polymorphisms may create partial deficiency states (reduced but not absent activity)
¶ Connections
- Beta-oxidation — LCAD catalyzes the first step in this four-enzyme spiral that sequentially shortens fatty acids
- fatty acid oxidation — broader process that LCAD initiates for long-chain substrates
- metabolic flexibility — LCAD function determines capacity to switch from glucose to fat metabolism
- mitochondria — exclusive location of LCAD and entire β-oxidation machinery
- lipolysis — provides free fatty acids that are converted to acyl-CoA substrates for LCAD
- CPT1A — transports long-chain acyl-CoA into mitochondria where LCAD awaits
- Intermittent fasting — physiological stimulus that upregulates LCAD expression via PPAR-α
- physical activity — activates LCAD through PGC-1α-mediated mitochondrial biogenesis
- ketogenesis — depends on LCAD to generate acetyl-CoA substrate for ketone body synthesis
- Insulin — suppresses LCAD activity and expression in fed state
- Glucagon — enhances LCAD expression during fasting through cAMP-PKA pathway
- PPAR signaling — PPAR-α is master transcriptional regulator of LCAD gene expression
- Adrenaline — acutely activates LCAD through β-adrenergic receptor signaling
- ATP production — LCAD-generated FADH₂ contributes to respiratory chain energy yield
- Chronic fatigue syndrome — some cases may involve subclinical fatty acid oxidation defects
- acetyl-CoA — end product of complete β-oxidation cycle that LCAD initiates
- Carnitine — required cofactor for acyl-CoA transport to LCAD location
- Oxidative Stress — LCAD deficiency causes accumulation of toxic lipid peroxides
- NLRP3 inflammasome — activated by accumulated long-chain acyl-CoA when LCAD insufficient
- Metabolic Depression — LCAD failure contributes to inability to generate energy from fats during stress
- hepatic ketogenesis — LCAD in liver mitochondria is essential for producing ketones during fasting
- Hunter-Gatherer Metabolism — LCAD capacity selected for in environments with intermittent food availability
¶ Module References
- Module 1